Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

被引：1
|
作者：
Younes, Anas [1 ]
Copeland, Amanda [2 ]
Fanale, Michelle A. [3 ]
Hagemeister, Fredrick [4 ]
Fayad, Luis [5 ]
Pro, Barbara [6 ]
Faria, Silvana C.
Ji, Yuan [7 ]
Medeiros, L. Jeffrey
Berry, Donald A.
Buglio, Daniela [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Clin Invest & Translat Res Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Ctr Hymphoma Myeloma, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Ctr Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Div Quantitat Sci, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.1763.1763
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1617 / 1617
页数：1
相关论文
共 50 条
  • [21] Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Kellner, Christian
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    HAEMATOLOGICA, 2015, 100 (04) : 544 - 550
  • [22] A PHASE IB STUDY EVALUATING THE COMBINATION OF ORAL PANOBINOSTAT (LBH589) WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Mateos, M. V.
    Spencer, A.
    Taylor, K.
    Lonial, S.
    De la Rubia, J.
    Facon, T.
    Bengoudifa, R.
    Klebsattel, M.
    Hazell, K.
    Bourquelot, P.
    Rossi, J. F.
    Harousseau, J. L.
    Jagannath, S.
    Wolf, J.
    San Miguel, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 158 - 158
  • [23] A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma
    Hosein, Peter J.
    Craig, Michael D.
    Tallman, Martin S.
    Boccia, Ralph V.
    Hamilton, Brian L.
    Lewis, Jonathan J.
    Lossos, Izidore S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 111 - 114
  • [24] Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
    Johnston, P. B.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Micallef, I. N.
    Porrata, L. F.
    LaPlant, B. R.
    Geyer, S. M.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study
    Zent, Clive S.
    Bowen, Deborah A.
    Conte, Michael J.
    LaPlant, Betsy R.
    Call, Timothy G.
    LEUKEMIA & LYMPHOMA, 2016, 57 (07) : 1585 - 1591
  • [26] Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma
    Umakanthan, Jayadev M.
    Iqbal, Javeed
    Batlevi, Connie L.
    Bouska, Alyssa
    Smith, Lynette M.
    Shostrom, Valerie
    Nutsch, Heather
    William, Basem M.
    Bociek, R. Gregory
    Lunning, Matthew
    Bierman, Philip
    Younes, Anas
    Armitage, James O.
    Vose, Julie M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (05) : 744 - 752
  • [27] Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Bitran, J. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 243 - 243
  • [28] Phase I/II trial of clofarabine in refractory and/or relapsed non-hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Gozun, P.
    Bitran, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma.
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    BLOOD, 2009, 114 (22) : 1481 - 1481
  • [30] Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
    Kambhampati, Swetha
    Fakhri, Bita
    Ai, Weiyun Z.
    Kaplan, Lawrence D.
    Tuscano, Joseph M.
    Wieduwilt, Matthew J.
    Sudhindra, Akshay
    Cavallone, Erika
    Reiner, Jesika
    Aoun, Charlie
    Castillo, Miguel
    Martinelli, Michelle
    Ta, Teresa
    Le, Diem
    Padilla, Michelle
    Crawford, Erika
    Andreadis, Charalambos B.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 139 - 146
12345